📣 VC round data is live. Check it out!

XtalPi Valuation Multiples

Discover revenue and EBITDA valuation multiples for XtalPi and similar public comparables like Shenzhen Intellifusion, Caris Life Sciences, Lemonade, UiPath and more.

XtalPi Overview

About XtalPi

XtalPi Holdings Ltd is an research platform company powered by artificial intelligence (AI) and robotics. It is dedicated to driving intelligent and digital transformation in the life sciences and materials sciences sectors. The company combines quantum physics, AI, cloud computing, and large-scale robotics to provide research & development solutions, services, and products for pharmaceuticals, biotechnology, renewable energy, and materials industries globally. The company has single segment that is intelligent robotics solutions and drug discovery solutions (including one-stop drug discovery solutions).


Founded

2017

HQ

China

Employees

809

Website

xtalpi.com

Financials (LTM)

Revenue: $126M
EBITDA: ($15M)

EV

$4B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

XtalPi Financials

XtalPi reported last 12-month revenue of $126M and negative EBITDA of ($15M).

In the same LTM period, XtalPi generated $83M in gross profit, ($15M) in EBITDA losses, and $16M in net income.

Revenue (LTM)


XtalPi P&L

In the most recent fiscal year, XtalPi reported revenue of $118M and EBITDA of $38M.

XtalPi is profitable as of last fiscal year, with gross margin of 70%, EBITDA margin of 32%, and net margin of 17%.

See analyst estimates for XtalPi
LTMLast FY202320242025202620272028
Revenue$126M$118M$26M$39M$118M
Gross Profit$83M$82M$7M$18M$82M
Gross Margin66%70%28%46%70%
EBITDA($15M)$38M($260M)($200M)$38M
EBITDA Margin(12%)32%(1018%)(514%)32%
EBIT Margin(38%)(44%)(426%)(269%)(56%)
Net Profit$16M$19M($280M)($222M)$18M
Net Margin13%17%(1098%)(569%)15%

Financial data powered by Morningstar, Inc.

XtalPi Stock Performance

XtalPi has current market cap of $5B, and enterprise value of $4B.

Market Cap Evolution


XtalPi's stock price is $1.14.

XtalPi share price decreased by 6.0% in the last 30 days, and increased by 94.8% in the last year.

See more trading valuation data for XtalPi
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$4B$5B-4.1%-6.0%-13.5%94.8%$0.00

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

XtalPi Valuation Multiples

XtalPi trades at 31.4x EV/Revenue multiple, and (256.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for XtalPi

EV / Revenue (LTM)


XtalPi Financial Valuation Multiples

As of May 8, 2026, XtalPi has market cap of $5B and EV of $4B.

XtalPi has a P/E ratio of 305.9x.

LTMLast FY202320242025202620272028
EV/Revenue31.4x33.6x154.8x101.4x33.6x
EV/EBITDAn/m103.7x(15.2x)(19.7x)103.7x
EV/EBIT(83.6x)(76.9x)(36.4x)(37.6x)(60.0x)
EV/Gross Profit47.7x48.3xn/m218.8x48.3x
P/En/mn/m(17.6x)(22.2x)n/m
EV/FCF—(111.1x)(38.7x)(50.0x)(111.1x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified XtalPi Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

XtalPi Margins & Growth Rates

XtalPi grew revenue by 22% but EBITDA decreased by 118% in the last fiscal year.

In the most recent fiscal year, XtalPi reported gross margin of 70%, EBITDA margin of 32%, and net margin of 17%.

See estimated margins and future growth rates for XtalPi

XtalPi Margins

Last FY202420252026202720282029
Gross Margin70%46%70%60%
EBITDA Margin32%(514%)32%(5%)
EBIT Margin(44%)(269%)(56%)(28%)
Net Margin17%(569%)15%7%
FCF Margin(30%)(203%)(30%)—

XtalPi Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth22%53%201%22%
Gross Profit Growth5%156%353%5%
EBITDA Growth(118%)(23%)(119%)(118%)
EBIT Growth(23%)(3%)(37%)(40%)
Net Profit Growth(50%)(21%)(108%)(46%)
FCF Growth—(23%)(55%)—

Data powered by FactSet, Inc. and Morningstar, Inc.

XtalPi Operational KPIs

XtalPi's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.

XtalPi's Rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

XtalPi's Rule of X is 51% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for XtalPi
LTMLast FY202320242025202620272028
Rule of 4018%18%———
Bessemer Rule of X63%51%———
Revenue per Employee—$0.1M———
Opex per Employee—$0.2M———
S&M Expenses to Revenue10%10%12%8%10%
G&A Expenses to Revenue48%51%31%53%51%
R&D Expenses to Revenue69%71%276%157%71%
Opex to Revenue—126%454%316%126%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Shenzhen Intellifusion22.4x—(1856.9x)—
Caris Life Sciences6.1x5.7x36.2x34.0x
Lemonade5.7x4.7x(35.7x)(43.9x)
UiPath2.6x2.6x11.1x10.7x
Intsig Information14.0x12.8x43.6x43.2x
Presight AI6.1x5.7x23.7x21.8x
SoundHound21.6x19.1x128.4x(84.5x)
Hinge Health6.3x5.6x30.5x24.5x

This data is available for Pro users. Sign up to see all XtalPi competitors and their valuation data.

Start Free Trial

XtalPi Funding History

Before going public, XtalPi raised $786M in total equity funding, across 7 rounds.

Last private valuation of XtalPi was $2B, after raising $400M in August 2021 from 5Y Capital, HOPU Investment Management Company, HSG, and 3 other investors.


XtalPi Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Aug-21Series D5Y Capital; HOPU Investment Management Company; HSG; OrbiMed; Sino Biopharmaceutical; Taihill Venture$400M$2BXtalPi is an AI-powered pharmaceutical technology company specializing in drug discovery and development through its ID4 (Intelligent Digital Drug Discovery and Development) platform, which leverages computational physics, quantum chemistry, machine learning, deep learning, natural language processing, and cloud computing to predict drug characteristics, model molecular compounds, and accelerate R&D pipelines for pharmaceutical partners. The platform has enabled hundreds of companies to advance research, resulting in dozens of new drug discoveries and over 100 small-molecule candidates identified. Key partnerships include Pfizer for AI drug modeling and crystal structure prediction, as well as 3D Medicines, GeneQuantum Healthcare, Huadong Medicine, and Signet Therapeutics. In August 2021, XtalPi completed a $400 million Series D funding round co-led by HOPU Investment Management (also referred to as HOPU Investments or RRJ in some reports) and OrbiMed Healthcare Fund Management, with participation from Sequoia Capital, Sino Biopharmaceutical, 5Y Capital, and others including previous backers like Tencent, Google, and SoftBank. This followed a Series C round of approximately $300-319 million less than a year prior, bringing the post-money valuation to over RMB 13 billion (approximately USD 2 billion). The investors noted the transformative potential of AI in drug discovery due to advances in computing power, positioning XtalPi to explore multiple verticals in pharmaceuticals. The fresh capital aims to expand collaborations with global pharmaceutical firms to identify and model high-potential molecular compounds, enhance the ID4 platform's predictive models (over 100 in total), and develop 'digital twin' simulations of drugs using lab data to predict clinical outcomes before trials. Post-Series C, XtalPi planned to integrate more experimental data into its AI systems for improved accuracy.
Sep-20Series C5Y Capital; PICC Capital Investment Management; SoftBank Vision Fund$319M$2BXtalPi is an artificial intelligence-based drug discovery and development company founded in 2014 by quantum physicists at MIT. The company's platform combines physics-based and data-driven models to predict molecular interactions and pharmacologic properties, incorporating over 100 algorithms to address drug properties relevant to clinical progression. The platform, called ID4, integrates virtual R&D simulations with real-world laboratory data to create what the company refers to as a digital-twin drug R&D system. On September 28, 2020, XtalPi announced an oversubscribed Series C funding round totaling $318.8 million. The round was co-led by SoftBank Vision Fund 2, PICC Capital, and Morningside Venture Capital, with participation from over a dozen additional global investment companies in banking and technology sectors. Existing investors including Tencent, Sequoia China, China Life, and SIG also contributed to the round. The company stated it would use proceeds to expand its AI and cloud computing-powered platform, taking a three-pronged approach to simultaneously develop algorithms, drug-like molecule databases, and computing power. XtalPi had previously raised $15 million in a Series B round announced in January 2018, followed by a $46 million Series B-1 extension in October 2018. The company had built strategic partnerships with top international pharmaceutical companies and reported that several AI drug discovery collaborations reached milestones in significantly shortened timeframes. XtalPi's team comprises multidisciplinary experts in physics, chemistry, pharmaceutical R&D, and algorithm design, with the platform designed to generate more drug candidates with fewer experiments in less time.
Oct-18Series BChina Life Healthcare Fund; HT Capital; SIG China (SIG Asia Investments); Yael Capital Management Limited$46M—XtalPi is a China-based artificial intelligence-equipped drug discovery platform founded in 2014 that utilizes physics-based and data-driven models to predict pharmaceutical and chemical properties of small-molecule drug candidates. The company's platform integrates quantum physics, AI, and robotics to improve drug design and development processes, enabling discovery of drug candidates with individualized pharmaceutical profiles. In October 2018, XtalPi closed a $46 million Series B-1 extension financing round led by China Life's Healthcare Fund, with participation from SIG China (a subsidiary of Susquehanna International Group), Yael Capital, and other existing investors. The round was designed to support market growth and expand the technology's application into new pharmaceutical research areas.
Jan-18Series BAlphabet; HSG; Tencent$15M——
Jan-16Series AFrees Fund; ZhenFund$1M——
Nov-15Series AFrees Fund; Tencent; ZhenFund$5M—XtalPi raised a $5 million Series A round led by Tencent in late 2015, with participation from ZhenFund and Frees Fund. Prior to this, the company received seed funding of $310,000 led by Renren. XtalPi, founded in 2014 by Chinese MIT graduates, develops an AI-powered platform combining artificial intelligence, quantum physics, and cloud computing to predict drug crystal structures and accelerate pharmaceutical R&D. The startup built an elastic high-performance computing cluster deployable across AWS, Tencent Cloud, Google Cloud, and Alibaba Cloud, supporting up to one million cores. XtalPi focuses on algorithmic solutions for drug research, including solid form drug design and chemical synthesis prediction. In 2015, Roche's Shanghai subsidiary became its first pharmaceutical partner. This Series A brought early total funding before subsequent rounds, with a $15 million Series B in 2018 from Sequoia China, Google, and Tencent, reaching $20 million total at that point.
Oct-15AngelMoatable$300K——

XtalPi M&A Activity

XtalPi has acquired 1 company to date.

Last acquisition by XtalPi was on June 13th 2025. XtalPi acquired Liverpool ChiroChem for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by XtalPi

Liverpool ChiroChem
Description
Liverpool ChiroChem is a contract research organization specializing in chiral small molecules for drug discovery. Liverpool, UK-headquartered LCC supplies building blocks, fragments, and screening compounds like chiral piperidines via asymmetric hydrogenation and Pd-coupling. The firm collaborates on synthetic route optimization for biotech and pharma R&D.
HQ CountryUnited Kingdom
HQ City
Liverpool
Deal Date13 Jun 2025
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all XtalPi acquisitions and their M&A valuation multiples.

Start Free Trial

XtalPi Investment Activity

XtalPi has invested in 10 companies to date.

Latest investment by XtalPi was on April 1st 2026. XtalPi invested in Xellar Biosystems in their $29M Series A round (EV/Revenue multiple of ).

See VC round multiples

Latest Investments by XtalPi

Xellar Biosystems
Dingxi Zhichuang
Deepin Technology
Newdel Biotech
Description
Xellar Biosystems is a biotechnology company developing wet artificial intelligence platforms for drug testing and treatment analysis. Its solutions integrate lab-on-a-chip technologies with machine learning to evaluate compound efficacy in real-time cellular environments. Based in Boston, the firm targets pharmaceutical research for faster iteration in oncology and infectious disease pipelines. Xellar partners with contract research organizations to validate its assays against traditional high-throughput screening methods.
Dingxi Zhichuang is an integrated circuit chip developer that designs, manufactures, and sells chips, products, and semiconductor equipment.
Deepin Technology is a Shanghai-based provider of artificial intelligence platforms for chemical materials research. The company integrates quantum chemistry simulations, high-throughput screening, and machine learning to accelerate molecule discovery and property prediction. Its Deep Principle platform supports virtual screening of millions of compounds daily and generative design for novel materials. Deepin Technology serves industries including pharmaceuticals, batteries, and semiconductors, with tools deployed in over 100 research labs across Asia. Founded in 2021, it collaborates with institutions like the Chinese Academy of Sciences.
Newdel Biotech is a China-based provider of drug discovery screening, biomedical R&D, and consulting services for pharmaceutical development.
HQ CountryUnited StatesChinaChinaChina
HQ City
Boston, MA
Shenzhen
Beijing
—
Deal Date1 Apr 202624 Mar 20263 Mar 202621 Jan 2026
RoundSeries AAngelSeries ASeries A
Raised$29Mundisclosedundisclosedundisclosed
InvestorsChina Life Private Equity Investment; Legend Capital; XtalPi; Yael Capital Management LimitedShanghai Future Industry Fund; XtalPiBaidu Ventures; Golden Ant Investment; Inspiration Capital; XtalPiXtalPi
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all XtalPi investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About XtalPi

When was XtalPi founded?XtalPi was founded in 2017.
Where is XtalPi headquartered?XtalPi is headquartered in China.
How many employees does XtalPi have?As of today, XtalPi has over 809 employees.
Who is the CEO of XtalPi?XtalPi's CEO is Jian Ma.
Is XtalPi publicly listed?Yes, XtalPi is a public company listed on HKEX.
What is the stock symbol of XtalPi?XtalPi trades under 02228 ticker.
When did XtalPi go public?XtalPi went public in 2024.
Who are competitors of XtalPi?XtalPi main competitors include Shenzhen Intellifusion, Caris Life Sciences, Lemonade, UiPath, Intsig Information, Presight AI, SoundHound, Hinge Health, Fermi, Privia Health.
What is the current market cap of XtalPi?XtalPi's current market cap is $5B.
What is the current revenue of XtalPi?XtalPi's last 12 months revenue is $126M.
What is the current revenue growth of XtalPi?XtalPi revenue growth (NTM/LTM) is 30%.
What is the current EV/Revenue multiple of XtalPi?Current revenue multiple of XtalPi is 31.4x.
Is XtalPi profitable?No, XtalPi is not profitable.
What is the current EBITDA of XtalPi?XtalPi has negative EBITDA and is not profitable.
What is XtalPi's EBITDA margin?XtalPi's last 12 months EBITDA margin is (12%).
What is the current EV/EBITDA multiple of XtalPi?Current EBITDA multiple of XtalPi is (256.8x).
How many companies XtalPi has acquired to date?As of May 2026, XtalPi has acquired 1 company.
What was the largest acquisition by XtalPi?None of the M&A deals XtalPi has completed have disclosed valuations.
What companies XtalPi acquired?XtalPi acquired Liverpool ChiroChem.
In how many companies XtalPi has invested to date?As of May 2026, XtalPi has invested in 10 companies.
What was the last XtalPi investment?On 1st April 2026 XtalPi invested in Xellar Biosystems, participating in a $29M Series A round, alongside China Life Private Equity Investment, Legend Capital, and Yael Capital Management Limited.
In what companies XtalPi invested in?XtalPi invested in PhoreMost, ReviR Therapeutics, Xellar Biosystems, META Pharmaceuticals, Signet Therapeutics, Leman Biotech, CytoCan Corp., Dingxi Zhichuang, Deepin Technology, and Newdel Biotech.

See public comps similar to XtalPi

Lists including XtalPi

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial